Patrick Bergin, MD
Cardiovascular Disease · Eugene, ORNPI 1225309685
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,349 of the $9,782 with a category attached, or 75.1%. 36 manufacturers reported payments, led by Medtronic at 37.3% of the total. Reporting peaked in 2019 at $3,204 and has fallen 78.3% since, to $694 in 2025.
Across 269 payments — averaging $36.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Boston Scientific$2K
- Abiomed$987
- Abbott$908
- Biotronik Inc.$460
- Novartis$355
- plus $2K from 30 others
What the payments were for
- Grants$1,12311%
- Travel & lodging$1,21212%
- Food & beverage$7,34975%
- Education$981%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 39 | $3,645 |
| Boston Scientific | 58 | $1,803 |
| Abiomed | 24 | $987 |
| Abbott | 33 | $908 |
| Biotronik Inc. | 18 | $460 |
| Novartis | 23 | $355 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $192 |
| AstraZeneca | 8 | $128 |
| Penumbra, Inc. | 1 | $108 |
| W. L. Gore & Associates, Inc. | 1 | $107 |
| Bristol Myers Squibb | 5 | $94 |
| Teleflex LLC | 3 | $80 |
| Shockwave Medical, Inc | 3 | $75 |
| Philips North America LLC | 2 | $73 |
| Regeneron Healthcare Solutions, Inc. | 5 | $70 |
| Pfizer | 5 | $66 |
| Johnson & Johnson | 4 | $58 |
| E.r. Squibb & Sons, L.L.C. | 4 | $58 |
| Boehringer Ingelheim | 3 | $58 |
| Amarin Pharma, Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 3 | $50 |
| Angiodynamics, Inc. | 1 | $49 |
| Medicomp Inc | 2 | $48 |
| Cardiva Medical, Inc. | 1 | $40 |
| Terumo Medical Corporation | 2 | $36 |
| Amgen | 2 | $35 |
| Edwards Lifesciences | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$1,618
- 3F$1,123
- Impella$270
- SYNERGY$206
- ASSURITY$136
- Xience Sierra Coronary Stent System$117
- Indigo$108
- CARDIOFORM Septal Occluder$107
- AVVIGO Guidance System$105
- LifeVest$103
How this compares
$9,782 in reported general payments places this provider in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 317 | $380,597 |
| EntrestoSacubitril/Valsartan | 66 | $90,567 |
| Repatha SureclickEvolocumab | 68 | $69,736 |
| XareltoRivaroxaban | 24 | $36,218 |
| Repatha SyringeEvolocumab | 22 | $13,991 |
| FarxigaDapagliflozin Propanediol | 13 | $8,342 |
| Metoprolol Succinate | 377 | $5,470 |
| Prasugrel Hcl | 33 | $3,051 |
| Flecainide Acetate | 73 | $2,805 |
| ClopidogrelClopidogrel Bisulfate | 255 | $2,685 |
| Torsemide | 89 | $2,462 |
| Atorvastatin Calcium | 206 | $2,381 |
| Ezetimibe | 95 | $2,008 |
| Irbesartan | 102 | $1,907 |
| Rosuvastatin Calcium | 185 | $1,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $66 | $380,597317 claims |
| NovartisEntresto | $355 | $90,56766 claims |
| Johnson & JohnsonXarelto | $58 | $36,21824 claims |
| AstraZenecaFarxiga | $128 | $8,34213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Eugene
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
- Stephen HeitnerPortland$105K
- Ian RiddockBend$81K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
- Kishor KhanalPortland$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.